Antiphospholipid antibody positivity and its potential impact on stent patency and long-term outcomes in central venous occlusive disease among hemodialysis patients: a call for targeted therapeutic strategies.
作者信息
Taghavi Maxime, Jacobs Lucas, Laureys Marc, Nortier Joëlle
机构信息
Department of Nephrology and Dialysis, Brugmann University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Faculty of Medicine, Laboratory of Experimental Nephrology, ULB Brussels, Belgium.
出版信息
Ren Fail. 2025 Dec;47(1):2486566. doi: 10.1080/0886022X.2025.2486566. Epub 2025 Apr 3.
Abstract
摘要
相似文献
1
Antiphospholipid antibody positivity and its potential impact on stent patency and long-term outcomes in central venous occlusive disease among hemodialysis patients: a call for targeted therapeutic strategies.抗磷脂抗体阳性及其对血液透析患者中心静脉闭塞性疾病支架通畅性和长期预后的潜在影响：呼吁采取针对性治疗策略。
Ren Fail. 2025 Dec;47(1):2486566. doi: 10.1080/0886022X.2025.2486566. Epub 2025 Apr 3.
2
Outcomes of the Gore Excluder abdominal aortic aneurysm leg endoprosthesis for treatment of central vein stenosis or occlusion in patients with chronic hemodialysis.戈尔腹主动脉瘤腿覆膜支架治疗慢性血液透析患者中心静脉狭窄或闭塞的结果。
J Vasc Surg Venous Lymphat Disord. 2020 Mar;8(2):195-204. doi: 10.1016/j.jvsv.2019.08.017.
3
Stent-Graft Length Is Associated with Decreased Patency in Treatment of Central Venous Stenosis in Hemodialysis Patients.支架移植物长度与血液透析患者中心静脉狭窄治疗中通畅率降低相关。
Ann Vasc Surg. 2019 Aug;59:225-230. doi: 10.1016/j.avsg.2019.01.024. Epub 2019 Apr 19.
4
Efficacy of covered stent placement for central venous occlusive disease in hemodialysis patients.覆膜支架置入治疗血液透析患者中心静脉闭塞性疾病的疗效。
J Vasc Surg. 2011 Sep;54(3):754-9. doi: 10.1016/j.jvs.2011.03.260. Epub 2011 Jun 12.
5
One-year outcomes and predictive factors for primary patency after stent placement for treatment of central venous occlusive disease in hemodialysis patients.血液透析患者中心静脉闭塞性疾病支架置入术后1年的主要通畅率结局及预测因素
Ther Adv Chronic Dis. 2022 Feb 17;13:20406223211063039. doi: 10.1177/20406223211063039. eCollection 2022.
6
Long-term outcomes of stenting superior cava and brachio-cephalic vein occlusion in hemodialysis patients with arteriovenous fistulas.动静脉内瘘透析患者上腔静脉及头臂静脉支架置入术的长期预后
J Vasc Surg Venous Lymphat Disord. 2025 Mar;13(2):102007. doi: 10.1016/j.jvsv.2024.102007. Epub 2024 Nov 20.
7
Risk factors for in-stent restenosis in maintenance hemodialysis patients with central venous occlusive disease and biomechanical assessment of stents.维持性血液透析患者中心静脉闭塞病变支架置入后再狭窄的危险因素及支架的生物力学评估。
J Vasc Access. 2024 May;25(3):943-952. doi: 10.1177/11297298221139640. Epub 2022 Dec 20.
8
A comparison of stenting versus hemodialysis reliable outflow graft for hemodialysis patients with recurrent central venous obstructions.支架置入术与血液透析可靠流出道移植物治疗复发性中心静脉阻塞血液透析患者的比较。
J Vasc Surg Venous Lymphat Disord. 2021 Sep;9(5):1136-1144. doi: 10.1016/j.jvsv.2021.01.001. Epub 2021 Jan 13.
9
Gianturco Z-stent placement for the treatment of chronic central venous occlusive disease: implantation of 208 stents in 137 symptomatic patients.Gianturco Z 支架置入治疗慢性中心静脉阻塞性疾病：137 例有症状患者植入 208 枚支架。
Diagn Interv Radiol. 2021 Jan;27(1):72-78. doi: 10.5152/dir.2020.19282.
10
Long-term results of stent-graft placement to treat central venous stenosis and occlusion in hemodialysis patients with arteriovenous fistulas.支架置入治疗血液透析患者动静脉瘘中心静脉狭窄和闭塞的长期结果。
J Vasc Interv Radiol. 2011 Sep;22(9):1240-5. doi: 10.1016/j.jvir.2011.06.002. Epub 2011 Jul 20.
本文引用的文献
1
Long-term outcomes of refractory central venous occlusive disease treated by stent deployment in patients undergoing maintenance hemodialysis.接受维持性血液透析的患者中，经支架置入治疗难治性中心静脉闭塞性疾病的长期预后。
Ren Fail. 2025 Dec;47(1):2463579. doi: 10.1080/0886022X.2025.2463579. Epub 2025 Feb 16.
2
Antiphospholipid antibodies positivity as a potential risk factor for restenosis following arteriovenous fistula stenting in hemodialysis patients: a pilot study.抗磷脂抗体阳性作为血液透析患者动静脉内瘘支架置入术后再狭窄的潜在危险因素：一项初步研究。
Front Med (Lausanne). 2025 Jan 3;11:1497810. doi: 10.3389/fmed.2024.1497810. eCollection 2024.
3
Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature.血液透析患者中与自体动静脉内瘘并发症相关的抗磷脂抗体：文献综述
Antibodies (Basel). 2024 Jan 2;13(1):1. doi: 10.3390/antib13010001.
4
2023 ACR/EULAR antiphospholipid syndrome classification criteria.2023 年 ACR/EULAR 抗磷脂综合征分类标准。
Ann Rheum Dis. 2023 Oct;82(10):1258-1270. doi: 10.1136/ard-2023-224609. Epub 2023 Aug 28.
5
The antiphospholipid syndrome may induce non-thrombotic internal jugular vein stenosis: two cases report.抗磷脂综合征可能诱发非血栓性颈内静脉狭窄：两例报告
BMC Neurol. 2021 Jan 7;21(1):9. doi: 10.1186/s12883-020-02035-1.
6
Stents Coated With Mammalian Target of Rapamycin Inhibitors (mTOR) Appear to Be the Best Choice in Patients With Antiphospholipid Syndrome and Myocardial Infarction.涂有雷帕霉素哺乳动物靶点抑制剂（mTOR）的支架似乎是抗磷脂综合征和心肌梗死患者的最佳选择。
J Clin Rheumatol. 2016 Aug;22(5):281. doi: 10.1097/RHU.0000000000000409.
7
Inhibition of the mTORC pathway in the antiphospholipid syndrome.抗磷脂综合征中 mTORC 通路的抑制。
N Engl J Med. 2014 Jul 24;371(4):303-12. doi: 10.1056/NEJMoa1312890.
8
Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint.血液透析血管通路功能障碍：细胞与分子视角
J Am Soc Nephrol. 2006 Apr;17(4):1112-27. doi: 10.1681/ASN.2005050615.
Zotero 插件